ArticlePatient preference and adherence2017

Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line.

Axel Svedbom et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.